ACOR Financial Facts
Net loss per share-diluted (earnings per share): -0.28Total net revenues: 135.61M
See Full Income Statement
Non-current portion of deferred cost of license revenue: 2.43M
Cash and cash equivalents: 127.94M
See Full Balance Sheet
Acorda Therapeutics, Inc. (ACOR) Earnings
|
Expand Research on ACOR
| Next EPS Date | N/A | EPS Growth Rate | -139.7% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | -188.2% | Revenue Growth Rate | +63.1% *Last Qtr. |
| Average % Move 1-Wk after EPS | -8.4% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2/15/18 |  |
Q417 | $0.61 | $1.05 | -$0.44 | $188.4M | $174.75M | = |  | | Details |
| 8/2/18 | |
Q218 | $1.40 | $0.72 | +$0.68 | $153.3M | $138.63M | = | | | Details |
10/22/15  |
|
Q315 | $0.31 | $0.15 | +$0.16 | $148.2M | $115.52M | N/A | | | Details |
| 10/31/18 | |
Q318 | $0.17 | -$0.02 | +$0.19 | $142.81M | $82.81M | = | | | Details |
| 10/31/17 | |
Q317 | $0.43 | $0.65 | -$0.22 | $141.07M | $150.64M | = | | | Details |
| 2/14/17 | |
Q416 | $0.05 | $0.11 | -$0.06 | $140.63M | $137.9M | = | | | Details |
| 7/27/17 | |
Q217 | $0.29 | $0.48 | -$0.19 | $139.44M | $140.07M | = | | | Details |
| 10/27/16 |
|
Q316 | -$0.04 | $0.11 | -$0.15 | $135.61M | $134.01M | N/A | | | Details |
